Lenvatinib-Pembrolizumab Combo Misses Goal in First-Line HCC Trial
(MedPage Today) -- Combining lenvatinib (Lenvima) with an immune checkpoint inhibitor in the first-line setting for unresectable hepatocellular carcinoma (HCC) failed to significantly improve survival outcomes in an international phase III trial... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - December 14, 2023 Category: Gastroenterology Source Type: news
Benign breast disease found on percutaneous biopsy ups cancer risk
Benign breast disease diagnosed through percutaneous biopsy increases the overall risk of developing breast cancer, according to research published December 13 in JAMA Surgery. A team led by Dr. Mark Sherman from the Mayo Clinic in Jacksonville, FL, found that presence of the disease on percutaneous biopsy is tied to a similar degree of increased breast cancer risk compared with surgically diagnosed benign breast disease. It also reported that the risks of both invasive breast cancer and ductal carcinoma in situ (DCIS) remained elevated among patients with the disease compared with the general population. “The finding...
Source: AuntMinnie.com Headlines - December 13, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: Womens Imaging Source Type: news
Oncotype Score Helps Avoid Unnecessary Radiation in DCIS Oncotype Score Helps Avoid Unnecessary Radiation in DCIS
Using a gene test to guide radiation decisions may reduce overtreatment in ductal carcinoma in situ.Medscape Medical News (Source: Medscape ObGyn and Womens Health Headlines)
Source: Medscape ObGyn and Womens Health Headlines - December 11, 2023 Category: OBGYN Tags: Hematology-Oncology Source Type: news
Il Gruppo Menarini presenta a SABCS 2023 nuovi dati dallo studio clinico EMERALD su ORSERDU ® (elacestrant) sulla sopravvivenza libera da progressione in sottogruppi clinicamente rilevanti di pazienti con carcinoma mammario metastatico (mBC) ER+, HER2- con mutazioni di ESR1
Questa nuova analisi post-hoc dello studio di fase 3 EMERALD ha valutato elacestrant nella popolazione endocrino-sensibile (durata dell'inibitore delle CDK4/6 di almeno 12 mesi) affetta da carcinomi con mutazioni di ESR1. Questa analisi mostra un miglioramento clinicamente significativo... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 9, 2023 Category: Pharmaceuticals Tags: TRI Source Type: news
Women With Very Early Breast Cancer May Safely Skip Radiation Rx: Study
FRIDAY, Dec. 8, 2023 -- Some women with a very early form of breast cancer known as ductal carcinoma in situ (DCIS) can safely skip follow-up radiation therapy after surgery, new research suggests.Results from a sophisticated genetic test are key... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 8, 2023 Category: General Medicine Source Type: news
CEM shows value as surveillance imaging tool
Contrast-enhanced mammography (CEM) has utility as a surveillance tool for women with a personal history of breast cancer, according to research presented December 6 at the San Antonio Breast Cancer Symposium. In her talk, Julia Matheson from the University of Melbourne in Australia shared research indicating that CEM surveillance leads to increased detection of clinically significant breast lesions, as well as lower interval cancer rates. “CEM increases the sensitivity of surveillance programs for women with a personal history of breast cancer,” Matheson said. Annual mammography with or without supplemental ultra...
Source: AuntMinnie.com Headlines - December 6, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: Breast Source Type: news
DBT plus mammo detects breast cancers with higher histologic grades
Digital breast tomosynthesis (DBT) plus synthesized mammography screening leads to higher detection of early-stage invasive breast cancers grades 2 or 3, according to research published December 5 in Radiology.
A team led by Stefanie Weigel, MD, from the University of Münster in Germany, found in its subanalysis of the Tomosynthesis plus Synthesized Mammography (TOSYMA) study that this combined method detects more cancers than mammography alone. The group also found that women ages 60-70 with dense breasts had the highest breast cancer rate in the study.
“These results suggest that DBT plus synthesized mammography scr...
Source: AuntMinnie.com Headlines - December 6, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: Subspecialties Breast Breast Imaging Source Type: news
ABK Biomedical Announces That its Eye90 Microspheres(R) Device Has Been Granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA)
HALIFAX, NS, Dec. 5, 2023 -- (Healthcare Sales & Marketing Network) - ABK Biomedical, Inc., an innovative, medical device company dedicated to the research, development, and commercialization of advanced imageable embolic therapies, announces its Eye90 mi... Devices, Oncology, FDA ABK Biomedical, Eye90 microspheres, Hepatocellular Carcinoma, embolic therapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 5, 2023 Category: Pharmaceuticals Source Type: news
STAT3 palmitoylation initiates a positive feedback loop that promotes the malignancy of hepatocellular carcinoma cells in mice | Science Signaling
Liver tumor growth in mice is exacerbated by a feed-forward loop triggered by the palmitoylation of STAT3. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - December 5, 2023 Category: Science Source Type: news
Why Is Cancer Focused CEL-SCI Stock Trading Higher Today?
CEL-SCI Corporation CVM announced that the British National Institute for Health and Care Excellence (NICE) has selected Multikine (Leukocyte Interleukin, Injection) to be evaluated as the potential new standard of care for squamous cell carcinoma of the head and neck (SCCHN) in the U.K. The NICE…#celscicorporationcvm #leukocyteinterleukin #multikine #geertkersten (Source: Reuters: Health)
Source: Reuters: Health - December 4, 2023 Category: Consumer Health News Source Type: news
Telix highlights first patient dosed with new renal cancer PET agent
Telix Pharmaceuticals is highlighting that the first patient has been dosed with the company's TLX250-CDx (Zr-89 DFO-girentuximab) for clear cell renal cell carcinoma, the most common and aggressive form of kidney cancer.The patient program is being conducted at Radboud University Medical Centre in Nijmegen, the Netherlands, and follows the completion of Telix's phase III ZIRCON study (Zirconium in Renal Cancer Oncology) which reported positive results, according to the firm.Telix is moving forward toward completing a Biologics License Application submission for TLX250-CDx with the U.S. Food and Drug Administration, it...
Source: AuntMinnie.com Headlines - December 4, 2023 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Subspecialties Nuclear Radiology Source Type: news
CEM confirms effectiveness of cryoablation
CHICAGO -- Contrast-enhanced mammography (CEM) confirms the effectiveness of ultrasound-guided cryoablation and could serve as a reliable annual follow-up exam, findings presented November 26 at the RSNA annual meeting suggest. In her presentation, Federica di Naro, MD, from Azienda Ospedaliero-Universitaria Careggi in Florence, Italy discussed her team’s results, which showed that combining CEM and re-evaluation with biopsy in selected breast cancer histology proves the efficacy of ultrasound-guided cryoabaltion and CEM’s reliability.“CEM is a valuable tool to define the effectiveness of cryoablation,” di Naro sai...
Source: AuntMinnie.com Headlines - December 1, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: Womens Imaging Breast Imaging RSNA 2023 Source Type: news
Drug Trials Snapshots: IMJUDO
IMJUDO is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody indicated in combination with durvalumab, for the treatment of adult patients with unresectable hepatocellular carcinoma. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - November 29, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Biomarker model predicts breast cancer risk without racial bias
CHICAGO -- A new breast cancer risk assessment technique that uses mammography biomarkers shows no racial bias, according to research presented November 29 at the RSNA meeting.The findings offer another way to foster breast cancer early detection, improve patient survival rates across different populations, and reduce disparity in survival rates, said study lead author Leslie Lamb, MD, of Massachusetts General Hospital (MGH) in Boston in a statement. “In the domain of precision medicine, risk-based screening has been elusive because we have not been able to accurately evaluate a woman’s risk of developing breast cance...
Source: AuntMinnie.com Headlines - November 29, 2023 Category: Radiology Authors: Liz Carey Tags: Subspecialties Womens Imaging Breast Imaging RSNA 2023 Source Type: news
F-18 fluciclovine PET/CT detects metastatic breast cancer
In this study, Mushtaq and colleagues enrolled 20 women with new or suspected recurrent ILC from a previous trial at Emory University. Patients had undergone PET/CT scans after IV administration of F-18 fluciclovine and Ga-68 PSMA on separate days. For comparison, conventional imaging included CT or bone scans in 13 patients and F-18 FDG-PET in seven patients.An image from Mushtaq's presentation showing a comparison between PET radiotracers in a patient with ILC. Image courtesy of Aliza Mushtaq, MD, Emory University.Three experts assessed radiotracer uptake per patient as well as in three regions per patient: ipsilateral a...
Source: AuntMinnie.com Headlines - November 27, 2023 Category: Radiology Authors: Will Morton Tags: Molecular Imaging Breast Imaging 2023 Source Type: news
